 MENLO PARK, Calif., Oct. 19, 2022 GLOBE NEWSWIRE -- AN2 Therapeutics, Inc. Nasdaq: ANTX, a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American IDSA IDWeek 2022 Conference from October 19-24, 2022 in Washington D.C. highlighting new data for epetraborole. AN2 Therapeutics is currently enrolling patients in its pivotal Phase 23 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex MAC lung disease, the most common form of nontuberculous mycobacterial NTM lung disease. 